



(51) International Patent Classification:

C07D 209/88 (2006.01) C07D 403/12 (2006.01)
C07D 401/04 (2006.01) C07D 403/14 (2006.01)
C07D 401/06 (2006.01) C07D 405/12 (2006.01)
C07D 401/12 (2006.01) C07D 417/04 (2006.01)
C07D 401/14 (2006.01) C07D 417/10 (2006.01)
C07D 403/04 (2006.01) A61K 31/403 (2006.01)
C07D 403/06 (2006.01) A61P 37/00 (2006.01)
C07D 403/10 (2006.01)

(21) International Application Number:

PCT/US2009/068415

(22) International Filing Date:

17 December 2009 (17.12.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/139,047 19 December 2008 (19.12.2008) US

(71) Applicant (for all designated States except US): **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LIU, Qingjie** [US/US]; c/o Bristol-Myers Squibb Company, Route 206


& Province Line Road, Princeton, New Jersey 08543 (US). **BATT, Douglas G.** [US/US]; c/o Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, New Jersey 08543 (US). **DELUCCA, George V.** [US/US]; c/o Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, New Jersey 08543 (US). **SHI, Qing** [CA/US]; c/o Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, New Jersey 08543 (US). **TEBBEN, Andrew J.** [US/US]; c/o Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, New Jersey 08543 (US).

(74) Agents: **VANATTEN, Mary K.** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS



(57) Abstract: Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, Formule (I) are useful as kinase modulators, including Btk modulation.



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*